# International state-funded testing — precedent for HRT inclusion **Phase:** 01 — Existing services **Last updated:** 2026-04-23 **Scope:** the two state-funded harm-reduction services worldwide that have extended their analytical infrastructure to anabolic-androgenic steroids. **Neither currently accepts HRT-for-gender-affirming-care as a routed-in intake class** — but both demonstrate that the legal framework, the instruments, and the operational model for community testing of injectable oil-based hormones is feasible at zero or near-zero cost to the user when the state is the operator. This file exists because the corpus's other international finding (`02-international-services.md` in `searches/`) is structurally important: outside the US/UK/IE axis, community HRT testing is essentially absent, and these two services are the only realistic extension vectors. They are the worked examples of what a state-funded HRT testing service *could* look like. --- ## Headline | Service | Country | Operator | Method | AAS price | Insurance? | HRT in scope? | |---|---|---|---|---|---|---| | **Zürich DIZ / SaferParty** | Switzerland | Drug Information Centre, City of Zürich | GC-MS | Free | N/A — public health service | **No, AAS only** | | **Anabolenpoli** | Netherlands | Spaarne Gasthuis, Haarlem | UPLC-QTOF-MS/MS | Insurance-covered with referral | Yes | **No, AAS only** | Both services are explicitly AAS-focused. A trans woman shipping a vial of testosterone enanthate from a UGL vendor would in principle be within the technical scope of either; a vial of estradiol valerate would not, because the substance is outside their stated intake categories rather than because their instruments couldn't analyse it. **The advocacy ask is policy scope, not technology.** --- ## Switzerland — Zürich DIZ / SaferParty AAS pilot **Operator:** Drug Information Centre (DIZ) Zürich, under the City of Zürich's Department of Social Welfare. Client-facing brand: **SaferParty.ch**. **Launched:** August 2023. **Status (2026):** Continued past pilot per the 2025 published evaluation; ongoing monitoring. **Legal frame:** Swiss Narcotics Act (NarcA / BetmG) four-pillar policy (prevention, therapy, harm reduction, repression) — drug-checking operates as an authorised service of the state itself, even where personal possession remains technically illegal. ### What it does - **Methods:** GC-MS (specific instrument model not publicly disclosed). Pilot evaluation reports a structured chemical analysis pipeline with photographic documentation of every sample. - **Accepted forms:** pills and injectables only. Other galenic forms (gels, transdermal patches) and unlabelled samples are rejected. - **Substances accepted:** anabolic-androgenic steroids (testosterone esters, boldenone, nandrolone, trenbolone, oxandrolone) plus β-sympathomimetics (clenbuterol). - **Substances NOT accepted:** no mention of estradiol, progesterone, or HRT-for-gender-affirming-care as a distinct intake category. - **Pricing:** Free. - **Anonymity:** Yes — anonymous sample-code intake. - **Intake channel:** In-person drop-off at the DIZ Zürich office (Selnaustrasse 10). ### Pilot results (Aug 2023 → 2025 evaluation) - **71 samples from 52 clients.** - **52% of analyzed AAS samples were fake or substandard:** 25% counterfeit, 27% failing quality standards. - Headline finding: the gray-market AAS supply chain in Switzerland is roughly half adulterated/substandard at the point of user consumption. This is the **first state-run drug-checking service anywhere to formally accept AAS as an intake class**. It is the most developed worked example of the legal and operational model that an HRT-equivalent service could adopt — same instruments, same anonymity workflow, different scope-of-acceptance language. ### Structured claim **Claim:** Zürich DIZ / SaferParty accepted 71 anabolic-androgenic-steroid samples from 52 clients via GC-MS in its August 2023 pilot, with 52% of samples found counterfeit or substandard; the program continued past pilot. - **Confidence:** **C1** (peer-reviewed pilot evaluation paper). - **Source:** Schori et al., *Harm Reduction Journal* 2025. PMC12147309. https://pmc.ncbi.nlm.nih.gov/articles/PMC12147309/ - **Date checked:** 2026-04-23 ### Sources - https://pmc.ncbi.nlm.nih.gov/articles/PMC12147309/ — Schori et al. (2025) pilot evaluation - https://en.saferparty.ch/ — operator's client-facing site - https://www.cpzh.ch/en/angebote/chemsex-drug-checking/ — DIZ partner program --- ## Netherlands — Anabolenpoli (AAS outpatient clinic, Haarlem) **Operator:** Spaarne Gasthuis hospital, Haarlem. Founder: **Dr Pim de Ronde**. **Founded:** 2011 — the world's longest-running dedicated AAS harm-reduction clinic. **Status (2026):** Active, ~10-year anniversary symposium documented; HARNAS clinical trial ongoing. **Legal frame:** Dutch healthcare regulation; testing is delivered as part of clinical research and routine harm-reduction follow-up. ### What it does - **Methods:** **UPLC-QTOF-MS/MS** for both identity and quantitation of supplied AAS samples. Standard pharmacology workup for hormonal panels (LH, FSH, estradiol, testosterone, prolactin) on patient blood. - **Accepted forms:** AAS injectables and orals from enrolled patients. - **Substances NOT accepted:** estradiol, HRT for gender-affirming care, peptides — out of clinic scope. - **Pricing:** Covered by Dutch health insurance with a GP or specialist referral. - **Intake channel:** Clinical referral; patient must enrol in the clinic and have their AAS use disclosed to a clinician. ### Published results - **HAARLEM study** (2018–) — multi-year cohort of AAS users with chemical analysis of supplied product. Published finding: *"The quality of the AAS used is strikingly low"* — adulteration and mislabelling are common. - **HARNAS trial** — ongoing intervention study. ### Structured claim **Claim:** Anabolenpoli (Spaarne Gasthuis Haarlem) has tested anabolic-steroid samples submitted by enrolled patients via UPLC-QTOF-MS/MS since 2011, in the framework of the HAARLEM cohort study; covered by Dutch health insurance with a referral; explicitly does not accept HRT-for-gender-affirming-care as a routine intake class. - **Confidence:** **C1** for the methods + study framework (multiple peer-reviewed publications); **C2** for "world's only dedicated AAS clinic" framing. - **Sources:** https://njmonline.nl/article_ft.php?a=1978&d=1301&i=215 (program overview); https://pubmed.ncbi.nlm.nih.gov/35938779/ (HAARLEM analytical paper); https://pubmed.ncbi.nlm.nih.gov/31663164/ (HAARLEM baseline); https://onderzoekmetmensen.nl/en/trial/52267 (HARNAS trial registration); https://peterbond.org/post/10-year-anniversary-symposium-dutch-outpatient-aas-clinic (symposium summary). - **Date checked:** 2026-04-23 --- ## Why this matters for the corpus 1. **Refutes the "no state will ever do this" priors.** Two precedents exist; neither is a covert pilot. Both publish peer-reviewed analytical and behavioural results. 2. **Demonstrates the technical sufficiency.** GC-MS is sufficient to characterise oil-based AAS injectables; UPLC-QTOF-MS/MS is sufficient at higher resolution. Both techniques are already deployed by the labs feeding testing.trans.diy (THR uses GC-MS) and by Janoshik. The instrumentation is not the bottleneck — the **scope-of-acceptance policy** is. 3. **Recalibrates `summary.md` Q1.** testing.trans.diy + Trans Harm Reduction + Artemis + Janoshik are not just the dominant community HRT-relevant labs — globally they are essentially **the only** community HRT-relevant labs. The Swiss and Dutch AAS programs are the most plausible international extension vectors for non-Anglo HRT testing but currently do not serve trans DIY users. 4. **Shapes the cost-benefit framework.** For users in CH or NL, free or insurance-covered AAS testing is in principle accessible — see `10-cost-benefit/when-to-diy-vs-outsource.md`. For testosterone-enanthate-in-grapeseed-oil specifically, this could change the in-house-vs-outsource math today; for estradiol esters it does not, until scope-of-acceptance is extended. 5. **Reframes the regulatory/legal map.** Switzerland's NarcA four-pillar framework and the Netherlands' insurance-funded clinical-research model are working examples that `07-regulatory-legal/jurisdictions.md` should reference as positive-case templates rather than only the US/UK/AU prohibition cases. --- ## What this file is NOT - It is not a routing recommendation for trans HRT users today. **Both services exclude HRT.** Submitting an estradiol vial would be rejected. - It is not a claim that the Swiss/Dutch programs are about to extend scope. There is no public roadmap for HRT inclusion in either; this is an advocacy opportunity, not a current option. - It does not generalise to other European harm-reduction services. Energy Control (Spain) explicitly excludes hormones; checkit! (Vienna) explicitly excludes AAS; DIMS (Netherlands) is recreational-drugs-only despite being run by Trimbos with similar instrumental capability. --- ## Cross-references - `01-existing-services/overview.md` — sharpened Energy Control entry to flag the hormone exclusion; brief summary of Switzerland + Netherlands here. - `01-existing-services/other-community-labs.md` — short cross-link. - `07-regulatory-legal/jurisdictions.md` — CH and NL added as worked legal-framework examples. - `10-cost-benefit/when-to-diy-vs-outsource.md` — note that CH/NL users have a free state-funded AAS pathway today. - `summary.md` — bottom-line decision framework references this file as the international precedent. - `searches/02-international-services.md` — full source pass with the 11-region survey from which this file is distilled. --- ## Sources - https://pmc.ncbi.nlm.nih.gov/articles/PMC12147309/ — Schori et al. *Harm Reduction Journal* (2025), Zürich AAS pilot evaluation — **C1** - https://en.saferparty.ch/ — DIZ/SaferParty operator site — C1 - https://www.cpzh.ch/en/angebote/chemsex-drug-checking/ — DIZ partner site — C1 - https://njmonline.nl/article_ft.php?a=1978&d=1301&i=215 — Anabolenpoli overview — C2 - https://pubmed.ncbi.nlm.nih.gov/35938779/ — HAARLEM UPLC-QTOF analytical paper — C1 - https://pubmed.ncbi.nlm.nih.gov/31663164/ — HAARLEM baseline cohort paper — C1 - https://onderzoekmetmensen.nl/en/trial/52267 — HARNAS trial registration — C1 - https://peterbond.org/post/10-year-anniversary-symposium-dutch-outpatient-aas-clinic — anniversary symposium summary — C2 All retrieved 2026-04-23.